EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference25 articles.
1. A randomized, phase III study of carboplatin /paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small-cell lung cancer: SWOG S0819;Herbst;Lancet,2018
2. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819;Redman;Clin Cancer Res,2012
3. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced non-small-cell lung cancer: Southwest Oncology Group Study S0342;Herbst;J ClinOncol,2010
4. Phase II trial of carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab in advanced non-squamous non-small-cell lung cancer SWOG S0536;Kim;J ThoracOncol,2013
5. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;J ClinOncol,2010
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01
2. Nuclear epidermal growth factor receptor as a therapeutic target;Exploration of Targeted Anti-tumor Therapy;2023-08-30
3. Case Report: Gene Heterogeneity in the Recurrent and Metastatic Lesions of a Myxoid Chondrosarcoma Patient With Aggressive Transformation;Frontiers in Genetics;2022-07-14
4. Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor;Cancers;2022-04-27
5. Elevation of Neutrophil-to-Lymphocyte Ratio Is a Significant Poor Prognostic Factor in Completely Resected Centrally Located Lung Squamous Cell Carcinoma;In Vivo;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3